MX2020007130A - Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. - Google Patents

Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.

Info

Publication number
MX2020007130A
MX2020007130A MX2020007130A MX2020007130A MX2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A
Authority
MX
Mexico
Prior art keywords
methods
metastatic cancers
axl
treating metastatic
decoy receptors
Prior art date
Application number
MX2020007130A
Other languages
English (en)
Inventor
Gail Mcintyre
David Prohaska
Ray Tabibiazar
Original Assignee
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aravive Biologics Inc filed Critical Aravive Biologics Inc
Publication of MX2020007130A publication Critical patent/MX2020007130A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

Se proporcionan composiciones y métodos para tratar un cáncer metastásico humano en un mamífero mediante la administración de una dosis terapéutica de una composición farmacéutica que inhibe la actividad de la proteína AXL, por ejemplo mediante la inhibición de la interacción de unión entre AXL y su ligando GAS6.
MX2020007130A 2017-11-04 2018-11-05 Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. MX2020007130A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762581671P 2017-11-04 2017-11-04
US201862618916P 2018-01-18 2018-01-18
US201862681944P 2018-06-07 2018-06-07
PCT/US2018/059218 WO2019090227A1 (en) 2017-11-04 2018-11-05 Methods of treating metastatic cancers using axl decoy receptors

Publications (1)

Publication Number Publication Date
MX2020007130A true MX2020007130A (es) 2021-02-15

Family

ID=66333375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007130A MX2020007130A (es) 2017-11-04 2018-11-05 Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.

Country Status (9)

Country Link
US (2) US20200289613A1 (es)
EP (1) EP3703731A4 (es)
JP (1) JP7286179B2 (es)
KR (1) KR20200085307A (es)
CN (1) CN111565742B (es)
AU (1) AU2018359863A1 (es)
CA (1) CA3080732A1 (es)
MX (1) MX2020007130A (es)
WO (1) WO2019090227A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230084893A1 (en) * 2020-01-06 2023-03-16 Aravive Inc METHODS OF TREATING CLEAR CELL RENAL CELL CARCINOMA (ccRCC) USING AXL DECOY RECEPTORS
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy
AU2021312139A1 (en) * 2020-07-19 2023-03-02 Aravive Inc. Diagnostic methods for cancer using AXL decoy receptors
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
CA3231358A1 (en) * 2021-09-11 2023-03-16 Gail Mcintyre Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
CN102281875B (zh) * 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
ES2928111T3 (es) * 2010-01-22 2022-11-15 Univ Leland Stanford Junior Inhibición de la señalización AXL en terapia antimetastásica
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
ES2862335T3 (es) * 2012-12-14 2021-10-07 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
CA2971406A1 (en) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
ES2848118T3 (es) * 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
US20180140679A1 (en) * 2016-11-23 2018-05-24 The Board Of Trustees Of The Leland Stanford Junior University Modulation of axl receptor activity in combination with cytoreductive therapy

Also Published As

Publication number Publication date
EP3703731A4 (en) 2021-07-21
JP7286179B2 (ja) 2023-06-05
AU2018359863A1 (en) 2020-07-02
RU2020116224A (ru) 2021-12-06
CN111565742A (zh) 2020-08-21
RU2020116224A3 (es) 2022-05-06
US20240009271A1 (en) 2024-01-11
CN111565742B (zh) 2024-03-01
WO2019090227A1 (en) 2019-05-09
CA3080732A1 (en) 2019-05-09
EP3703731A1 (en) 2020-09-09
US20200289613A1 (en) 2020-09-17
KR20200085307A (ko) 2020-07-14
JP2021502334A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2017007321A (es) Terapias de combinacion.
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
MX2016008362A (es) Combinaciones farmaceuticas.
WO2011091305A3 (en) Inhibition of axl signaling in anti-metastatic therapy
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
Froeling et al. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2018001515A (es) Combinaciones de un anticuerpo ox40 y un modulador tlr4 y usos de las mismas.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2017015532A (es) Terapia de combinacion pac-1.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2022008289A (es) Metodos de tratamiento del carcinoma de celulas renales de celulas claras (ccrcc) utilizando receptores señuelo axl.